Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems
Key claim: Makers of certain class II clinical toxicology test systems can now sell those devices without first filing a 510(k) premarket notification with FDA, subject to listed limitations.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is publishing an order setting forth its final determination to exempt certain class II clinical toxicology test systems from premarket notification (510(k)) requirements, subject to certain limitations. This exemption from 510(k) requirements, subject to certain limitations, is immediately in effect for such devices. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations. FDA is amending the classification language within the Code of Federal Regulations (CFR) for certain class II clinical toxicology test systems to reflect this final determination. FDA is publishing this order in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Why this matters
510(k) exemptions remove a premarket filing step for a defined subset of Class II devices, which can shorten time to market and reduce manufacturer costs without altering postmarket safety requirements. For the clinical toxicology niche affected, labs and providers may see faster availability of test systems, while FDA retains general controls and the listed limitations as safeguards.